Docetaxel and Capecitabine in Advanced Gastric Cancer
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Up to date there is no worldwide accepted standard chemotherapy for the 1st-line treatment of
advanced or metastatic gastric cancer.A combination of epirubicin, cisplatin and 5-FU (ECF)
is the best examined combination and widely used. Recent studies (Thuss-Patience et al, J.
Clin. Oncol. 2005) could show that a combination of docetaxel and 5-FU might be similarly
effective as ECF. 5-FU and docetaxel +/- cisplatin combinations are investigated by many
groups and may be a future reference treatment. Many data suggest that 5-FU infusion can be
replaced by oral capecitabine with equal efficacy.
As docetaxel/5-FU is probably similarly effective as epirubicin/cisplatin/5-FU and a
replacement of 5-FU infusion by capecitabine makes the chemotherapy more comfortable for the
patient we investigate in this study a chemotherapy of docetaxel and capecitabine as 1st-line
therapy for metastatic or advanced gastric cancer.